Dyadic International, Inc. (NASDAQ:DYAI – Get Rating) was the target of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 255,500 shares, a decrease of 7.7% from the October 15th total of 276,800 shares. Approximately 1.3% of the company’s stock are sold short. Based on an average trading volume of 32,900 shares, the days-to-cover ratio is currently 7.8 days.
Dyadic International Stock Performance
DYAI opened at $1.83 on Thursday. The company has a market cap of $52.27 million, a P/E ratio of -4.36 and a beta of 0.49. Dyadic International has a one year low of $1.58 and a one year high of $4.98. The business’s 50-day simple moving average is $2.01 and its 200-day simple moving average is $2.45.
Institutional Trading of Dyadic International
A number of large investors have recently made changes to their positions in DYAI. Forefront Analytics LLC lifted its position in Dyadic International by 38.9% during the 2nd quarter. Forefront Analytics LLC now owns 46,771 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 13,100 shares during the period. Commonwealth Equity Services LLC lifted its position in Dyadic International by 37.6% during the 1st quarter. Commonwealth Equity Services LLC now owns 28,018 shares of the biotechnology company’s stock worth $84,000 after acquiring an additional 7,650 shares during the period. Finally, Captrust Financial Advisors acquired a new stake in Dyadic International during the 1st quarter worth approximately $45,000. 13.50% of the stock is owned by institutional investors and hedge funds.
About Dyadic International
Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.
- Get a free copy of the StockNews.com research report on Dyadic International (DYAI)
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- International Game Technology is Well Worth the Gamble
- Use The Airbnb Stock Implosion to Your Advantage
- Why Lowe’s Is Up And Home Depot Down
- The TJX Companies Could Break Out To New Highs
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.